ORIC® Pharmaceuticals to Participate in Upcoming Investor Conferences
ORIC Pharmaceuticals (NASDAQ: ORIC), a clinical stage oncology company, has announced its participation in two major investor conferences in June 2025. The company will engage in fireside chats at:
- The Jefferies Global Healthcare Conference on June 4, 2025, at 12:50 p.m. ET
- The Goldman Sachs 46th Annual Global Healthcare Conference on June 10, 2025, at 10:00 a.m. ET
Webcasts of both discussions will be accessible through ORIC's investor relations website and will remain available for replay for 90 days after the events.
ORIC Pharmaceuticals (NASDAQ: ORIC), un'azienda oncologica in fase clinica, ha annunciato la sua partecipazione a due importanti conferenze per investitori nel giugno 2025. La società parteciperà a colloqui informali durante:
- La Jefferies Global Healthcare Conference il 4 giugno 2025 alle 12:50 ET
- La Goldman Sachs 46th Annual Global Healthcare Conference il 10 giugno 2025 alle 10:00 ET
Le trasmissioni in diretta di entrambi gli incontri saranno disponibili sul sito web delle relazioni con gli investitori di ORIC e potranno essere riviste in replay per 90 giorni dopo gli eventi.
ORIC Pharmaceuticals (NASDAQ: ORIC), una empresa oncológica en etapa clínica, ha anunciado su participación en dos importantes conferencias para inversores en junio de 2025. La compañía participará en charlas informales en:
- La Jefferies Global Healthcare Conference el 4 de junio de 2025 a las 12:50 p.m. ET
- La Goldman Sachs 46th Annual Global Healthcare Conference el 10 de junio de 2025 a las 10:00 a.m. ET
Las transmisiones en vivo de ambas charlas estarán disponibles en el sitio web de relaciones con inversores de ORIC y podrán reproducirse durante 90 días después de los eventos.
ORIC Pharmaceuticals (NASDAQ: ORIC)는 임상 단계의 종양학 회사로서 2025년 6월 두 개의 주요 투자자 컨퍼런스에 참여할 것이라고 발표했습니다. 회사는 다음 행사에서 대담에 참여할 예정입니다:
- 2025년 6월 4일 오후 12시 50분(ET) Jefferies Global Healthcare Conference
- 2025년 6월 10일 오전 10시(ET) Goldman Sachs 46th Annual Global Healthcare Conference
두 행사 모두 ORIC 투자자 관계 웹사이트를 통해 생중계되며, 이벤트 종료 후 90일간 다시보기로 제공됩니다.
ORIC Pharmaceuticals (NASDAQ : ORIC), une société d'oncologie en phase clinique, a annoncé sa participation à deux grandes conférences pour investisseurs en juin 2025. La société prendra part à des discussions informelles lors de :
- La Jefferies Global Healthcare Conference le 4 juin 2025 à 12h50 ET
- La Goldman Sachs 46th Annual Global Healthcare Conference le 10 juin 2025 à 10h00 ET
Les webdiffusions des deux discussions seront accessibles via le site des relations investisseurs d'ORIC et resteront disponibles en replay pendant 90 jours après les événements.
ORIC Pharmaceuticals (NASDAQ: ORIC), ein klinisch tätiges Onkologieunternehmen, hat seine Teilnahme an zwei wichtigen Investorenkonferenzen im Juni 2025 angekündigt. Das Unternehmen wird an folgenden Gesprächsrunden teilnehmen:
- Die Jefferies Global Healthcare Conference am 4. Juni 2025 um 12:50 Uhr ET
- Die Goldman Sachs 46th Annual Global Healthcare Conference am 10. Juni 2025 um 10:00 Uhr ET
Webcasts beider Diskussionen sind über die Investor-Relations-Webseite von ORIC zugänglich und stehen für 90 Tage nach den Veranstaltungen zur Wiedergabe bereit.
- None.
- None.
SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, May 27, 2025 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced that management will participate in the following investor conferences in June:
- Jefferies Global Healthcare Conference – Participating in a fireside chat on Wednesday, June 4, 2025, at 12:50 p.m. ET
- Goldman Sachs 46th Annual Global Healthcare Conference – Participating in a fireside chat on Tuesday, June 10, 2025, at 10:00 a.m. ET
Webcasts of the discussions will be available through the investor section of the company’s website at www.oricpharma.com. Replays of the webcasts will be available for 90 days following the event.
About ORIC Pharmaceuticals, Inc.
ORIC Pharmaceuticals is a clinical stage biopharmaceutical company dedicated to improving patients’ lives by Overcoming Resistance In Cancer. ORIC’s clinical stage product candidates include (1) ORIC-944, an allosteric inhibitor of the polycomb repressive complex 2 (PRC2) via the EED subunit, being developed for prostate cancer, and (2) ORIC-114, a brain penetrant inhibitor that selectively targets EGFR exon 20, HER2 exon 20 and EGFR atypical mutations, being developed across multiple genetically defined cancers. Beyond these two product candidates, ORIC® is also developing multiple precision medicines targeting other hallmark cancer resistance mechanisms. ORIC has offices in South San Francisco and San Diego, California. For more information, please go to www.oricpharma.com, and follow us on X or LinkedIn.
Contact:
Dominic Piscitelli, Chief Financial Officer
dominic.piscitelli@oricpharma.com
info@oricpharma.com
